Papel de la ribavirina en la terapia libre de interferón frente al virus de la hepatitis C

Morillas, Rosa María; Masnou, Helena; Ardèvol, Mercè; López, Dulce

doi:10.1016/j.gastrohep.2017.07.003

Cited by 2 publications

(2 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1 The HCV infection has an extraordinarily ability to persist in up to 80.0% of individuals. 2 Chronic HCV infection is closely associated with cirrhosis and hepatocellular carcinoma (HCC) development (15)(16)(17)(18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30).0% of cases within 20 years, and 2-4% risk/year respectively), 3,4 both leading causes of liver transplantation (LT) or liver-related deaths. 5 Chronic HCV infection may also occur in patients with the hepatitis B virus (HBV) infection, since they share the same transmission modes.…”

Section: Introductionmentioning

confidence: 99%

“…HCV compartmentalization may have important implications in the pathogenesis and could explain universal HCV recurrence after LT 21 and/or lower response to DAA-treatment in patients with advanced liver disease, particularly those with HCC. 15,22,23 Since limited data are available on HCV compartmentalization, we analysed HCV-variability in terms of HCV-RNA amount, quasispecies and the resistance-associated substitutions (RASs) prevalence, in plasma (PL), hepatic tumoral (TT), and non-tumoral (NT) tissue samples in patients undergoing LT or hepatic resection (HR), because of HCC and/or cirrhosis. In addition, we also aimed to evaluate whether HBV core antibody (HBcAb) positivity could play an influencing role in HCV compartmentalization.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

HCV resistance compartmentalization within tumoral and non‐tumoral liver in transplanted patients with hepatocellular carcinoma

Sorbo

Carioti

Bellocchi

et al. 2019

Liver International

View full text Add to dashboard Cite

Background & aims:We investigated the HCV-RNA amount, variability and prevalence of resistance-associated substitutions (RASs), in plasma, hepatic tumoral and non-tumoral tissue samples in patients undergoing liver-transplant/hepatic-resection (LT/HR), because of hepatocellular carcinoma and/or cirrhosis. Methods:Eighteen HCV-infected patients undergoing LT/HR, 94.0% naïve to direct-acting antivirals (DAAs), were analysed. HCV-RNA was quantified in all compartments. NS3/NS5A/NS5B in plasma and/or in tumoral/non-tumoral tissues were analysed using Sanger and Ultra-deep pyrosequencing (UDPS, 9/18 patients). RASs prevalence, genetic-variability and phylogenetic analysis were evaluated. Results: At the time of LT/HR, HCV-RNA was quantifiable in all compartments of DAA-naïve patients and was generally lower in tumoral than in non-tumoral tissues (median [IQR] = 4.0 [1.2-4.3] vs 4.3[3.1-4.9] LogIU/µg RNA; P = 0.193).The one patient treated with sofosbuvir + ribavirin represented an exception with HCV-RNA quantifiable exclusively in the liver, but with higher level in tumoral than in non-tumoral tissues (51 vs 7 IU/µg RNA). RASs compartmentalization was found by Sanger in 4/18 infected-patients, and by UDPS in other two patients. HCVcompartmentalization resulted to be associated with HBcAb-positivity (P = 0.013).UDPS showed approximately higher genetic-variability in NS3/NS5A sequences in all compartments. Phylogenetic-analysis showed defined and intermixed HCVclusters among/within all compartments, and were strongly evident in the only non-cirrhotic patient, with plasma and non-tumoral sequences generally more closely related. Conclusions:Hepatic compartments showed differences in HCV-RNA amount, RASs and genetic variability, with a higher segregation within the tumoral compartment. | 1987 SORBO et al. S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section at the end of the article. How to cite this article: Sorbo MC, Carioti L, Bellocchi MC, et al. HCV resistance compartmentalization within tumoral and non-tumoral liver in transplanted patients with hepatocellular carcinoma.

show abstract